Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

NCT04566328 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT04566328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04566328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Phase 3
Overall status
Recruiting
Start date
February 24, 2021
Completion date
December 31, 2027
Enrollment
1,450 (estimated)
Sites
647

Conditions

As the registry lists them; a condition with its own page is linked.

plasma cell myeloma, riss stage i plasma cell myeloma, riss stage ii plasma cell myeloma